/PRNewswire/ Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today.
Erasca, Inc (ERAS) Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in
Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the blood of patients following treatment.
The test, called Guardant Reveal, developed by precision oncology company Guardant Health, is tumor-uninformed because, unlike previous tests for circulating tumor DNA (ctDNA) in the blood, this test does not require knowing the particular mutations that were present in the patient s tumor.